Spectroscopy Market 2030: $31B and Clinical Diagnostics Growth

The global spectrometry market was valued at $19.71 billion in 2024 and is projected to reach $31.23 billion by 2030, growing at a CAGR of 7.7% (Grand View Research, 2025). That growth is not evenly distributed. Pharmaceutical quality control - historically the dominant application - is growing steadily. Food safety is accelerating. But clinical diagnostics, the segment that barely registered five years ago, is where the structural shift is happening.

This article maps the market as it stands in late 2026: who the major players are, where the revenue comes from, where it is going, and why the bottleneck for clinical spectroscopy adoption has shifted from hardware to software.

Market Size and Segmentation

The top-line numbers

Multiple research firms track the spectroscopy market, and their methodologies differ. The ranges are informative:

The variance stems from how broadly each firm defines "spectroscopy." Grand View Research's $19.71B figure covers spectrometry instruments, consumables, software, and services. Spherical Insights uses a broader definition that includes adjacent analytical technologies. The Grand View figure is the most widely cited and the one we will reference throughout this article.

The U.S. market alone accounts for $7.29 billion (2024), with North America holding 41.6% of global revenue. The U.S. market is projected to reach $11.6 billion by 2030 at a CAGR of 7.8%, growing slightly faster than the global average, driven by pharmaceutical R&D spending and the concentration of academic research institutions.

Asia-Pacific is the fastest-growing region at a CAGR of approximately 7.65%, fueled by expanding pharmaceutical manufacturing capacity in China and India and increasing government research funding across the region. Europe holds 25-28% of the global market, with growth driven by regulatory compliance requirements and strong biotech innovation in Germany, the UK, and Scandinavia.

By application

Pharmaceutical analysis dominates, accounting for 34.9% of market revenue in 2024 (Grand View Research). But the growth rates tell a different story:

Clinical diagnostics is not broken out as a standalone segment in most market reports - it is typically grouped under "biomedical" or "pharmaceutical." This in itself tells you something: the segment is new enough that market research firms have not yet given it its own category. When they do, it will signal that clinical spectroscopy has moved from "emerging" to "established."

By technology

Mass spectrometry is the largest technology segment, driven by its established role in clinical chemistry and proteomics. But for point-of-care diagnostics - the segment that matters for clinical deployment - vibrational spectroscopy (FTIR, Raman, NIR) is where the action is.

Raman spectroscopy deserves attention. At $612 million in 2024, it is a fraction of the overall market, but its 6.95% CAGR and trajectory toward an estimated $1.2 billion by 2035 reflect the growing interest in non-contact, label-free molecular analysis - exactly the capability that clinical diagnostics demands.

For a detailed technical comparison of how FTIR, Raman, and NIR differ from an integration perspective, see our engineering-focused modality comparison.

Clinical Diagnostics: The Emerging Growth Segment

Why now

Spectroscopy has been used in research laboratories for decades. What is new is the convergence of three developments that make clinical deployment viable.

1. AI-powered spectral classification

Traditional spectroscopy required a trained spectroscopist to interpret spectra. Machine learning changes this fundamentally. A trained model can classify a spectrum in milliseconds, transforming spectroscopy from a research technique requiring expert interpretation into a push-button diagnostic tool that any medical laboratory scientist can operate. For a deep dive on the AI side, see our article on AI-powered spectral classification.

2. Instrument miniaturization and cost reduction

Handheld Raman spectrometers that cost $5,000-$30,000 and chip-scale NIR sensors under $5,000 have brought instrument costs below the threshold for clinical deployment. A decade ago, a Raman spectrometer cost $100,000+. Today, devices like the Forward Edge AI Blaise (handheld Raman, ~$800 target price point, $0.50/test) aim to make spectroscopy disposable-economics.

3. Regulatory precedent

In January 2024, DermaSensor received FDA De Novo authorization for an AI-powered elastic scattering spectroscopy device that detects skin cancers (melanoma, basal cell carcinoma, squamous cell carcinoma) with 96% sensitivity across a 1,000+ patient, 22-center clinical trial led by Mayo Clinic. This is the landmark event: the first FDA authorization of a spectroscopy-based AI diagnostic device. It establishes a regulatory pathway that other spectroscopy diagnostics can reference.

Additional clinical spectroscopy devices in the pipeline include Vita Imaging's AURA (Raman-based skin cancer detection, multi-site FDA clinical validation study launched January 2025) and multiple Raman-based devices for intraoperative cancer margin assessment. Published clinical performance for Raman spectroscopy in surgical guidance shows 80% sensitivity and 90% specificity for intraoperative cancer detection, with gastric tissue diagnostics reaching 94.4% sensitivity and 96.3% specificity.

The FDA pathway

The absence of a cleared predicate for most spectroscopy-based diagnostics means De Novo classification - a more rigorous (and expensive) pathway than 510(k). But DermaSensor's clearance now serves as a reference point. Future spectroscopy diagnostics can point to it as evidence that the FDA is willing to authorize AI-powered spectral analysis devices.

For clinical laboratories, the LDT (Laboratory Developed Test) pathway remains available: CLIA-certified labs can develop and validate their own spectroscopy-based tests without FDA clearance. As the FDA's LDT regulatory framework continues to evolve, this pathway provides a faster route to clinical use, particularly for academic medical centers and reference laboratories developing novel spectroscopy assays. See our analysis of the FDA's evolving LDT framework and SaMD classification boundaries for the regulatory details.

The Hardware vs. Software Bottleneck

This is the central thesis: the instruments are ready for clinical use. The software is not.

Hardware is mature

Bruker, Thermo Fisher, Horiba, Renishaw, and Agilent manufacture world-class spectrometers. A Bruker Alpha II FTIR ($25,000-$40,000), a Horiba LabRAM Raman ($50,000-$150,000), or a Si-Ware NeoSpectra NIR sensor ($500-$2,000) can all acquire clinically useful spectra with adequate signal-to-noise, resolution, and reproducibility.

The hardware is not the bottleneck. You can buy a spectrometer today that is technically capable of performing clinical diagnostics. What you cannot buy is the software that turns it into a deployable clinical instrument.

What instrument vendors provide - and what they do not

Every major instrument vendor provides acquisition software: Bruker OPUS, Thermo OMNIC, Horiba LabSpec, Renishaw WiRE. These are powerful analytical tools designed for scientists. They control the instrument, acquire spectra, perform basic data processing, and visualize results.

What they do not provide:

This gap exists for structural reasons, not because instrument vendors are negligent. They are instrument companies. Their core competency is optics, lasers, detectors, and signal processing. Clinical software - HL7 integration, EHR connectivity, billing automation, regulatory documentation - is a different business requiring different expertise, different sales channels, and different regulatory obligations. We wrote a detailed analysis of why instrument vendors do not build clinical software.

The software revenue opportunity

The spectroscopy software market was valued at approximately $280 million in 2025 and is projected to reach $481 million by 2030 at a CAGR of 11.45% (GM Insights, 2025). This growth rate - nearly double the hardware market's CAGR - reflects the shift in value from instruments to intelligence.

But the $280-$481 million figure covers all spectroscopy software: instrument control, data analysis, method development, library search. Clinical workflow software - the layer that connects the spectrometer to the clinical environment - is a subset that barely exists today. It is greenfield.

The Major Players and Their Positions

Understanding where the major companies are focused reveals where the gaps are.

Thermo Fisher Scientific ($44.6B revenue, FY2025)

The largest company in the analytical instruments space by a wide margin. Thermo Fisher's Instruments segment generated $7.3 billion in FY2025 (16.4% of total revenue), but spectroscopy is a small fraction of that - the company's scale comes from mass spectrometry, chromatography, electron microscopy, and life sciences consumables.

In spectroscopy, Thermo Fisher is strong in FTIR (Nicolet product line), Raman (DXR), UV-Vis, and XRF. Their clinical focus is through the clinical diagnostics division (immunoassay, clinical chemistry, microbiology), where they compete with Roche, Abbott, and Siemens Healthineers. Thermo has not connected its spectroscopy and clinical diagnostics businesses - the spectroscopy instruments sell to research labs, not clinical labs.

Bruker Corporation ($3.4B revenue, FY2024-2025)

Bruker is the closest to clinical spectroscopy of the major vendors. The IR Biotyper - an FTIR-based microbial identification system - has CE-IVD marking in Europe and is deployed in clinical microbiology labs. Bruker also acquired Tornado Spectral Systems (Raman) in January 2024, signaling interest in expanding its spectroscopy portfolio.

Bruker's FY2025 guidance of $3.43-$3.50 billion represents modest growth. The CALID (Chemical, Applied Markets, Life Science, and Diagnostics) segment at $285.8 million (Q2 2025) is where clinical spectroscopy sits. The IR Biotyper is the only commercially deployed clinical spectroscopy product from a major vendor, but it ships with Bruker's own data management (ONet), not a full clinical workflow platform.

Agilent Technologies ($6.95B revenue, FY2025)

Agilent's Life Sciences & Diagnostics Markets segment ($3.22B, FY2024) is heavily weighted toward chromatography and mass spectrometry for pharmaceutical and clinical chemistry. Agilent's spectroscopy portfolio (Cary UV-Vis, Cary FTIR) serves research and QC markets. Their diagnostics business focuses on pathology and genomics - not spectroscopy-based diagnostics.

Revvity (formerly PerkinElmer, $2.76B revenue, FY2024)

The PerkinElmer name now belongs to the analytical instruments business that was spun off when the parent company rebranded to Revvity. Revvity's diagnostics segment ($1.5B, FY2024) focuses on newborn screening, reproductive health, and applied genomics - not spectroscopy. The analytical instruments (Spectrum Two FTIR, Frontier FTIR/NIR) target pharmaceutical and industrial markets.

Horiba Scientific (~$275M in scientific instruments, FY2024)

Horiba is the Raman specialist. The LabRAM and XploRA product lines are among the most widely used research Raman systems globally. Horiba's parent company (~$2.1B total revenue) spans automotive, semiconductor, and environmental markets. The scientific instruments segment is small relative to the parent, and Horiba has not pursued clinical spectroscopy applications with dedicated products.

Horiba restructured its business segments in FY2025 to Energy & Environment, Bio & Healthcare, and Materials & Semiconductor - the "Bio & Healthcare" renaming may signal increased interest in life science applications, but no clinical spectroscopy products have been announced.

Renishaw (GBP 691.3M revenue, FY2024)

Renishaw's spectroscopy business (within "Analytical instruments & medical devices," GBP 43.2M in FY2024) is focused on Raman microscopy for research. The 2025 launch of the Strada Intelligent Raman Microscope, featuring AI-assisted analysis, and the 2026 introduction of TRRS technology in the inVia system show investment in making Raman more accessible. But Renishaw's spectroscopy customers are materials scientists and academic researchers, not clinicians.

The gap

None of these companies - Thermo Fisher, Bruker, Agilent, Revvity, Horiba, Renishaw - provide a clinical workflow software platform that sits between their instruments and clinical information systems. Bruker comes closest with the IR Biotyper + ONet combination, but even that does not provide HL7/FHIR messaging, billing automation, or a clinician-facing UI designed for non-spectroscopists.

This is not a failure of imagination. It is a structural market gap: instrument companies sell to scientists, and clinical software companies (Epic, Cerner, Orchard, LabWare) sell to hospitals. The layer between the spectrometer and the clinical system is no one's core business.

Investment Trends

Private equity interest

The most significant recent transaction is KKR's $6.5 billion acquisition of Spectris, completed in December 2025, after a bidding war with Advent International. Spectris is an analytical instruments company (Malvern Panalytical, HBK, Omega Engineering). The deal valuation - and the competitive bidding - signals strong PE confidence in the analytical instruments sector's growth trajectory.

Notable M&A activity includes:

• Spectris acquired Micromeritics for $630 million (August 2024)
• Bruker acquired Tornado Spectral Systems, a Raman specialist (January 2024)

The M&A pattern reflects a consolidation trend: large instrument companies acquiring smaller specialists to fill technology gaps.

Venture capital

Spectroscopy-adjacent diagnostics startups saw increased funding in 2024-2025:

• DermaSensor raised $16 million in Series B (2024-2025), bringing total funding to $43 million, following FDA De Novo clearance of their spectroscopy-based skin cancer detection device
• HyperSpectral raised $8.5 million Series A (2024) and $7 million Series A-2 (October 2025), totaling $19 million for AI-powered spectral pathogen detection
• Optical spectroscopy startups collectively raised $35.2 million across 4 equity rounds in 2024, a 75.5% increase over 2023 funding levels (Tracxn)

The broader spectroscopy sector includes over 6,000 companies, 37,000+ patents filed, and 170+ active investors across 830+ funding rounds (StartUs Insights, 2026). The near-infrared spectroscopy sub-sector is showing 10.4% growth in company count, reflecting particular interest in NIR-based clinical and consumer health applications.

SBIR/STTR funding

The U.S. SBIR/STTR program - a critical funding source for early-stage diagnostics companies - experienced a gap in authorization from October 2025 to April 2026. The program was reauthorized on April 13, 2026, with the next receipt date set for September 5, 2026. NCI's stated areas of interest include in vitro and in vivo diagnostics, companion diagnostics, and prognostic technologies, all applicable to spectroscopy-based diagnostics.

Companies that secured SBIR Phase I/II awards before the authorization gap have a head start: they have non-dilutive funding and validated concepts. Monitoring SBIR awards for spectroscopy-related diagnostics (searchable at sbir.gov) is one of the most reliable ways to identify early-stage companies that will need clinical workflow software.

Where the Value Is Shifting

From hardware to software

Hardware accounts for 61.8% of spectroscopy market revenue today (Grand View Research, 2024). Software accounts for roughly 2-3% of total market revenue - approximately $280-500 million out of a $19.7 billion market. But software is growing at 11.45% CAGR versus approximately 7-8% for hardware.

This is a classic technology market value migration. As instruments commoditize (more vendors, lower price points, converging specifications), the differentiation shifts to the intelligence layer: the software that processes spectra, trains models, manages workflows, and delivers actionable results. The same pattern has played out in:

• Genomics - sequencing hardware commoditized; bioinformatics software captured the value
• Medical imaging - scanner hardware from GE/Siemens/Philips commoditized; AI-based image analysis from Viz.ai, Aidoc, Tempus captured new value
• Industrial sensors - sensor hardware commoditized; IoT analytics platforms captured the value

The clinical software wedge

For clinical spectroscopy specifically, the software opportunity is not just "better analysis tools." It is the entire clinical integration layer:

1. Clinical workflow management - patient identification, specimen tracking, test ordering, result review, quality control
2. EHR connectivity - HL7v2/FHIR messaging to LIS and EHR systems
3. Regulatory compliance - 21 CFR Part 11 audit trails, IEC 62304 lifecycle documentation, SaMD regulatory support
4. Multi-vendor instrument abstraction - a single platform that works across Bruker, Thermo, Horiba, and Renishaw instruments
5. Multi-site data infrastructure - centralized spectral databases, analytics, and model management across laboratory networks

Each of these is table stakes for clinical deployment and absent from every instrument vendor's offering. The company that provides this layer captures recurring software revenue from every clinical spectroscopy deployment, regardless of which instrument is underneath. This is exactly the integration layer that a dedicated spectroscopy workflow platform delivers.

For the technical architecture of how this integration works, see our articles on clinical workflow architecture, HL7v2 for spectroscopy, and FHIR R4 integration.

Implications for Startups and Investors

Where the defensible positions are

Instrument manufacturing is a capital-intensive, engineering-intensive business with established leaders and high barriers to entry. Startups like Forward Edge AI (handheld Raman) and Si-Ware (MEMS-based NIR) succeed by targeting specific form factors or price points that incumbents have not addressed, but they compete against companies with decades of optical engineering expertise and global distribution.

AI/ML classification models for specific clinical applications are defensible through training data (proprietary spectral databases), clinical validation (published sensitivity/specificity), and regulatory clearance. DermaSensor's model for skin cancer detection is defensible because replicating their 1,000+ patient, 22-center validation study requires years and millions of dollars.

Clinical workflow software is defensible through integration depth. Each HL7 interface to a specific LIS, each instrument adapter for a specific vendor's API, each deployment at a clinical site builds switching costs. A platform that manages workflows across FTIR, Raman, and NIR instruments from multiple vendors - with working integrations to Epic, Cerner, and Orchard - becomes the path of least resistance for every subsequent clinical deployment.

What business models work

Per-instrument or per-test SaaS aligns revenue with the customer's scale. Implementation fees ($15,000-$25,000) cover the integration work. Monthly platform fees ($3,000-$5,000/site) provide predictable recurring revenue. Per-test fees ($1-$2) scale with volume. This model works because the alternative - custom development at $250,000-$500,000 per deployment - is unacceptable for most clinical labs and diagnostic startups.

Instrument vendor partnerships provide distribution leverage. Every lab that deploys a clinical spectroscopy platform buys an instrument from Bruker, Thermo, Horiba, or Renishaw. The platform makes the instrument more valuable, so instrument vendors are incentivized to recommend it. This is non-competitive, mutually beneficial channel development.

The competitive landscape evolution

The most likely consolidation pattern: one or more instrument vendors will eventually acquire a clinical workflow software platform rather than build one. The build-vs-buy economics favor acquisition - clinical software requires healthcare IT expertise (HL7, FHIR, HIPAA, 21 CFR Part 11) that instrument companies do not have and would take years to develop. The precedent exists: Bruker acquired EIPC for its clinical workflows adjacent to MALDI-TOF, and similar acquisitions are likely for spectroscopy.

The window for independent clinical spectroscopy software companies is now, before instrument vendors make their acquisition moves and before the first major FDA clearances trigger a land rush for deployed platforms. Startups that establish working deployments, validated integrations, and reference customers during this window will be the acquisition targets - or the independent platforms - when the market scales.

Key Takeaways

The spectroscopy market does not lack instruments. It lacks the software layer that turns those instruments into clinical tools. The companies that build that layer - and build it across vendors and modalities - will capture a disproportionate share of the value as clinical spectroscopy moves from research to routine deployment.

Part of the SpectraDx technical blog.